Evogene (EVGN) Payables (2016 - 2025)

Evogene (EVGN) has disclosed Payables for 10 consecutive years, with $639000.0 as the latest value for Q4 2025.

  • Quarterly Payables fell 47.96% to $639000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $639000.0 through Dec 2025, down 47.96% year-over-year, with the annual reading at $639000.0 for FY2025, 47.96% down from the prior year.
  • Payables hit $639000.0 in Q4 2025 for Evogene, down from $1.2 million in the prior quarter.
  • In the past five years, Payables ranged from a high of $1.8 million in Q4 2023 to a low of $639000.0 in Q4 2025.
  • Historically, Payables has averaged $1.2 million across 5 years, with a median of $1.2 million in 2024.
  • Biggest five-year swings in Payables: skyrocketed 72.3% in 2023 and later plummeted 47.96% in 2025.
  • Year by year, Payables stood at $1.5 million in 2021, then fell by 29.19% to $1.0 million in 2022, then surged by 72.3% to $1.8 million in 2023, then plummeted by 31.2% to $1.2 million in 2024, then tumbled by 47.96% to $639000.0 in 2025.
  • Business Quant data shows Payables for EVGN at $639000.0 in Q4 2025, $1.2 million in Q4 2024, and $1.8 million in Q4 2023.